Status 2 patients had poor prognosis without mechanical circulatory support

Area of Science:

• Cardiology
• Heart Failure Management
• Mechanical Circulatory Support

Background:

• Mechanical circulatory support (MCS) indication is debated for less critically ill Status 2 heart failure (HF) patients.
• Status 2 patients often face poor prognoses, comparable to those requiring inotropes or MCS.

Purpose of the Study:

• To evaluate the prognosis of Status 2 heart failure patients.
• To identify predictors of survival in Status 2 patients.
• To assess the potential benefit of ventricular assist device (VAD) therapy in this cohort.

Main Methods:

• Retrospective analysis of 183 Stage D HF patients listed for heart transplantation (Status 1 or 2).
• Comparison of survival rates between patients with and without MCS.
• Cox regression analysis to identify survival predictors in Status 2 patients.

Main Results:

• Status 2 patients (n=38) showed similar poor prognosis to inotrope-dependent (n=54) and MCS-dependent (n=91) patients.
• Only 10.5% of Status 2 patients received eventual VAD implantation.
• Patients receiving VAD (n=92) demonstrated improved 4-year survival compared to non-MCS Status 1 and 2 patients.
• Plasma B-type natriuretic peptide (BNP) >740 pg/mL was the sole significant predictor of 4-year survival in Status 2 patients (HR 8.267).
• Ten Status 2 patients died, primarily from sudden death (hemodynamic compromise or ventricular fibrillation).

Conclusions:

• Prognosis for Status 2 patients is poor, often due to sudden death without MCS.
• Status 2 patients with elevated plasma BNP levels are potential candidates for continuous-flow VAD therapy.